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Abstract
Insulin resistance increases renal oxidant production by upregulating NADPH oxi-
dase 4 (Nox4) expression contributing to oxidative damage and ultimately albuminu-
ria. Inhibition of the renin-angiotensin system (RAS) and activation of glucagon-like 
peptide-1 (GLP-1) receptor signalling may reverse this effect. However, whether 
angiotensin receptor type 1 (AT1) blockade and GLP-1 receptor activation improve 
oxidative damage and albuminuria through different mechanisms is not known. Using 
insulin-resistant Otsuka Long-Evans Tokushima Fatty (OLETF) rats, we tested the 
hypothesis that simultaneous blockade of AT1 and activation of GLP-1r additively de-
crease oxidative damage and urinary albumin excretion (UalbV) in the following groups: 
(a) untreated, lean LETO (n = 7), (b) untreated, obese OLETF (n = 9), (c) OLETF + an-
giotensin receptor blocker (ARB; 10 mg olmesartan/kg/d; n = 9), (d) OLETF + GLP-1 
mimetic (EXE; 10 µg exenatide/kg/d; n = 7) and (e) OLETF + ARB +exenatide (Combo; 
n = 6). Mean kidney Nox4 protein expression and nitrotyrosine (NT) levels were 30% 
and 46% greater, respectively, in OLETF compared with LETO. Conversely, Nox4 pro-
tein expression and NT were reduced to LETO levels in ARB and EXE, and Combo re-
duced Nox4, NT and 4-hydroxy-2-nonenal levels by 21%, 27% and 27%, respectively. 
At baseline, UalbV was nearly double in OLETF compared with LETO and increased 
to nearly 10-fold greater levels by the end of the study. Whereas ARB (45%) and 
EXE (55%) individually reduced UalbV, the combination completely ameliorated the 
albuminuria. Collectively, these data suggest that AT1 blockade and GLP-1 receptor 
activation reduce renal oxidative damage similarly during insulin resistance, whereas 
targeting both signalling pathways provides added benefit in restoring and/or further 
ameliorating albuminuria in a model of diet-induced obesity.
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1  | INTRODUC TION
The prevalence of chronic kidney disease (CKD) in the US adult pop-
ulation was 14.8% from 2011 to 2014.1 Many factors are associated 
with the development of CKD including older age, hypertension, car-
diovascular disease, obesity and diabetes mellitus (DM), with the lat-
ter co-existing in 30%-40% of individuals with CKD.2 Although DM 
is a primary factor for the development of CKD, the deterioration of 
renal function precedes the development of overt DM. Therefore, 
factors that precede the development of DM such as obesity, the 
metabolic syndrome and insulin resistance are major risk factors for 
the development of CKD.3,4 Obesity and its comorbidities are major 
risk factors because they inappropriately activate the renin-angio-
tensin system (RAS),5 increase production of oxidants and/or de-
crease the expression of antioxidant enzymes leading to oxidative 
stress.6,7 In patients with CKD further deterioration of renal function 
is associated with higher urinary angiotensinogen excretion (UAgtV), 
an index of intrarenal angiotensin II activity.8,9 Additionally, CKD 
patients present with higher plasma 8-isoprostane levels (a marker 
of oxidant stress status in vivo),10 which were inversely correlated 
with lower estimated glomerular filtration rates (eGFR).11 However, 
the mechanisms by which inappropriately activate RAS and oxida-
tive stress compromise renal health, and ultimately, function remain 
unclear in insulin-resistant conditions.
Glucagon-like peptide-1 (GLP-1) is an incretin hormone that acts 
through the GLP-1 receptor (GLP-1r), which is expressed in many tis-
sues including the kidneys.12-14 GLP-1 increases insulin secretion in a 
glucose-dependent manner,15 suggesting that it may be a useful ther-
apeutic agent for targeting the maladies associated with the metabolic 
syndrome and insulin resistance. GLP-1r agonists and dipeptidyl pep-
tidase inhibitors may also serve as novel antihypertensive agents by 
increasing Na+ excretion16-18 and may have protective effects against 
diabetic nephropathy by downregulating NADPH oxidase (Nox) en-
zymes.19-21 Nox enzymes are major producers of oxidants in the kidney 
under high glucose or high angiotensin II (Ang II) conditions leading to 
oxidative damage.21,22 Of the seven Nox isoforms, Nox1, Nox2 and 
Nox4 are expressed in the rodent kidney,23 with Nox4 being the most 
prominent in the renal cortex.24 Collectively, these relationships sug-
gest that increased renal Nox4 mediates oxidative renal injury during 
insulin resistance and that GLP-1 based therapies may be beneficial in 
preventing the development of CKD.
Monotherapy of either angiotensin receptor blockade (ARB) or 
GLP-1 receptor agonist decreased urinary albuminuria excretion in 
patients with DM, suggesting that these two signalling pathways 
may be involved in the manifestation of renal injury.25,26 While the 
blockade of AT1 and the activation of the GLP-1r ameliorate renal 
oxidative stress, their combined effects on oxidant/antioxidant sig-
nalling, and subsequently, on renal injury during insulin resistance 
remain unexamined. Using insulin-resistant Otsuka Long-Evans 
Tokushima Fatty (OLETF) rats, a model of diet-induced obesity, in-
sulin resistance and elevated intrarenal RAS,27-30 we tested the hy-
pothesis that simultaneous blockade of AT1 and activation of GLP-1r 
additively decrease oxidative damage and albuminuria.
2  | RESULTS
2.1 | OLETF rats are characterized by increased 
arterial pressure, insulin resistance and urinary 
angiotensinogen excretion
Body mass (BM), absolute and relative fat masses, absolute kidney 
mass and UAgtV were measured to assess whether AT1 blockade and 
activated GLP-1r signalling blunted the development of obesity, insulin 
resistance and elevated intrarenal RAS. Data on BM, the homeostasis 
model assessment of insulin resistance (HOMA-IR), and UAgtV have 
been previously published,31 but are briefly included here for complete-
ness. On day 41, mean arterial pressure (MAP) was 22% higher in OLETF 
than in LETO and EXE was not significantly different from OLETF. 
Notwithstanding, MAP was 22% and 27% lower in ARB and Combo, 
respectively, compared with OLETF (Table 1).31 Additionally, BM was 
34% greater in OLETF compared with LETO, whereas ARB and EXE had 
no significant effect on BM compared with OLETF. On the other hand, 
BM was 10% lower in Combo compared with OLETF (Table 1). Mean 
absolute and relative fat masses were greater in OLETF compared with 
LETO. However, there were no significant changes among the treat-
ment groups and OLETF (Table 1). Mean absolute kidney mass was 45% 
greater in OLETF compared with LETO. Nevertheless, there were no 
significant changes among the treatment groups and OLETF (Table 1). 
Fasting plasma glucose (FPG) and fasting plasma insulin (FPI) were 32% 
and 128% higher, respectively, in OLETF than in LETO. FPI was not sig-
nificantly different in ARB, EXE and Combo compared with OLETF. Yet, 
FPG was 9% lower in ARB compared with OLETF, and EXE and Combo 
were not significantly different from OLETF (Table 2).31 Mean plasma 
leptin was nearly 4-fold greater (P < .001) in OLETF compared with 
LETO, and ARB and Combo reduced (P < .05) values 48% and 52%, re-
spectively, but still almost double of LETO (P < .05) (Table 2). EXE had no 
detectable effect on plasma leptin with values similar to OLETF (Table 2). 
HOMA-IR was 240% greater in OLETF compared with LETO; however, 
there were no significant changes among ARB, EXE and Combo com-
pared with OLETF (Table 2).31 On day 40, mean UAgtV was greater in 
OLETF compared with LETO (748 ± 66 vs 135 ± 10 ng/day; P < .05) 
and was lower in ARB (332 ± 43 ng/d; P < .05), EXE (287 ± 25 ng/d; 
P < .05) and Combo (313 ± 26 ng/d; P < .05) compared with OLETF.31 
Collectively, these results demonstrate that OLETF rats are character-
ized by obesity, insulin resistance and elevated intrarenal RAS.
2.2 | AT1 blockade and GLP-1r activation reduce 
Nox4 protein expression in the kidney
Kidney Nox4 protein expression, superoxide dismutase (SOD), catalase 
and glutathione peroxidase (GPx) activities were measured to assess 
whether AT1 blockade and activated GLP-1r signalling improved renal 
oxidant potential and antioxidant balance. Mean Nox4 protein expres-
sion was 30% greater in OLETF compared with LETO and was 20%, 
15% and 21% lower in ARB, EXE and Combo, respectively (Figure 1). 
Mean SOD activity was 50% lower in OLETF compared with LETO, 
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whereas activity was 81% and 100% higher in ARB and Combo, re-
spectively, compared with OLETF (Figure 2A). Although SOD activity 
was 61% greater in EXE compared with OLETF, it was not statistically 
significant (P = .065) (Figure 2A). Mean catalase and GPx activities 
were similar among all groups (Figure 2B,C). Collectively, these results 
suggest that blockade of AT1 and activation of GLP-1r-mediated sig-
nalling share a common pathway to improve Nox4 protein expression 
in the kidney. Furthermore, these results suggest that the degree of 
insulin resistance-associated renal dysfunction in OLETF rats is suf-
ficient to impair the superoxide radical quenching capacity (SOD), but 
not sufficient to impair the antioxidant capacity of the hydrogen per-
oxide quenching enzymes (catalase and GPx).
2.3 | AT1 blockade and GLP-1R activation improve 
renal injury
Urinary 8-isoprostane excretion (U8-isoV), renal nitrotyrosine (NT) 
and 4-hydroxy-2-nonenal (4-HNE) were measured to determine 
whether AT1 blockade and activated GLP-1r signalling reduced the 
obesity-associated systemic and renal oxidative damage. Mean U8-
isoV was 102% higher in OLETF compared with LETO (Figure 3A) but 
was not different among the treatment groups and OLETF (Figure 3A). 
Mean renal NT was 46% greater in OLETF compared with LETO, 
whereas levels were reduced by 25%, 22% and 27% in ARB, EXE and 
Combo, respectively, compared with OLETF (Figure 3B). Mean renal 
4-HNE levels were not different among LETO, OLETF, ARB and EXE; 
however, they were 27% lower in Combo compared with OLETF 
(Figure 3C). Collectively, these results suggest that the insulin resist-
ance associated with OLETF rats is characterized by systemic oxida-
tive stress that is not reversed by either AT1 blockade or activation of 
GLP-1r signalling. However, renal protein nitration is reversed by AT1 
blockade and activation of GLP-1r signalling in a non-additive fashion.
2.4 | AT1 blockade in conjunction with GLP-1r 
activation ameliorates albuminuria in OLETF rats
Urinary albumin excretion (UalbV), urinary albumin:creatinine ratio 
(ACR) and the PAS-positive area in glomeruli were assessed to 
 
LETO
(n = 7)
OLETF
(n = 9)
ARB
(n = 9)
EXE
(n = 7)
Combo
(n = 6)
MAP (mm/Hg) 94 ± 2 115 ± 3* 90 ± 3** 110 ± 1*,*** 84 ± 2*,**,****
Body mass (g) 425 ± 14 568 ± 13* 530 ± 6* 547 ± 11* 509 ± 19*,**
Retrofat (g) 6.0 ± 0.4 22.5 ± 1.9* 19.5 ± 1.4* 19.3 ± 1.5* 16.1 ± 1.1*
Relative retrofat 
(g/ 100 g BM)
1.6 ± 0.1 4.2 ± 0.2* 3.9 ± 0.2* 3.9 ± 0.2* 3.5 ± 0.1*
Epi-fat (g) 6.0 ± 0.2 11.3 ± 1.0* 11.3 ± 0.8* 10.4 ± 0.7* 8.6 ± 0.7*
Relative epi-fat 
(g/100 g BM)
1.6 ± 0.1 2.1 ± 0.1* 2.3 ± 0.1* 2.1 ± 0.1* 1.9 ± 0.1
Total fat (g) 12 ± 0.6 33.8 ± 2.6* 30.9 ± 2.2* 29.6 ± 2.1* 24.8 ± 1.6*
Relative total fat 
(g/100 g BM)
3.1 ± 0.1 6.3 ± 0.3* 6.2 ± 0.4* 5.9 ± 0.3* 5.4 ± 0.2*
Kidney mass (g) 1.1 ± 0.03 1.6 ± 0.07* 1.5 ± 0.03* 1.6 ± 0.04* 1.6 ± 0.04*
Abbreviations: epi, epididymal; Retro, retroperitoneal.
*P < .05, vs LETO. 
**P < .05 vs OLETF. 
***P < .05 vs ARB. 
****P < .05 vs EXE. 
TA B L E  1   Mean body mass, 
absolute and relative fat masses 
and absolute kidney mass in LETO, 
OLETF, OLETF + olmesartan (ARB), 
OLETF + exenatide (EXE) and 
OLETF + combination (Combo) group of 
rats at 16 wk of age
TA B L E  2   Mean (± SE) fasting plasma biochemical and hormone measurements, and calculated HOMA-IR in LETO, OLETF, 
OLETF + olmesartan (ARB), OLETF + exenatide (EXE) and OLETF + combination (Combo) group of rats at 16 wk of age
 LETO (n = 7) OLETF (n = 9) ARB (n = 9) EXE (n = 7) Combo (n = 6)
Glucose (mmol/dL) 5.6 ± 0.2 7.4 ± 0.2* 6.7 ± 0.1*,** 7.1 ± 0.2* 7.0 ± 0.1*
Insulin (mmol/L) 130 ± 18 296 ± 31* 229 ± 28 325 ± 45* 300 ± 27*
HOMA-IR (relative units) 0.8 ± 0.1 2.7 ± 0.4* 1.6 ± 0.2 2.5 ± 0.4* 2.3 ± 0.2
Leptin (ng/mL) 2.33 ± 0.21 9.08 ± 0.83* 4.76 ± 0.67*,** 6.84 ± 0.97* 4.35 ± 0.36*,**
Creatinine (mg/dL) 0.71 ± 0.06 0.35 ± 0.04* 0.38 ± 0.04* 0.40 ± 0.05* 0.52 ± 0.07*
Abbreviation: HOMA-IR, homeostasis model assessment of insulin resistance.
*P < .05, vs LETO. 
**P < .05 vs OLETF. 
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determine the potential benefits of AT1 blockade and activated 
GLP-1r signalling to the insulin resistance-associated nephropathy. 
At baseline, mean UalbV was almost double in OLETF compared with 
LETO, and levels increased nearly 10-fold in OLETF over the next 
6 wks while they remained unchanged in LETO (Figure 4). Mean 
UalbV decreased nearly 45% and 55% in ARB and EXE, respectively, 
compared with OLETF, and COMBO completely ameliorated the in-
crease (Figure 4). At baseline, mean ACR was 54% greater in OLETF 
compared with LETO. On day 40, mean ACR was 12.4-fold greater 
in OLETF compared with LETO and increased 2.4-fold compared 
with its baseline levels. When corrected for creatinine excretion, 
the changes in ARB and EXE were not significantly reduced com-
pared with OLETF, suggesting that subtle, non-significant changes 
in glomerular filtration were just sufficient enough to abolish the 
statistical difference. However, mean ACR was reduced 83% in 
Combo compared with OLETF, suggesting that the improvements 
in albuminuria were more profound and not a function of alterna-
tions in filtration alone. Periodic acid-Schiff (PAS)-positive area in 
glomeruli among the groups detected no significant changes that 
would reveal overt renal damage or protective benefits of the 
treatments at this stage of the insulin resistance-associated renal 
injury (Figure 5). Collectively, these results suggest that the pro-
tective effects of AT1 blockade and GLP-1r activation against the 
insulin resistance-associated albuminuria in OLETF rats are addi-
tive. Furthermore, the increased ACR is not associated with overt 
glomerular injury at this stage of the insulin resistance. The changes 
in UcrtV were not statistically different among the groups at the end 
of the study.
3  | DISCUSSION
The prevalence of CKD in the adult US population was 14.8% from 
2011 to 2014.1 Although many factors are associated with the de-
velopment of CKD, DM is a primary risk factor and accounts for the 
majority of cases of end-stage renal disease in the United States.32 
Furthermore, DM with the early development of kidney disease re-
duces lifespan by 16 years, whereas DM and early kidney disease 
on their own reduce lifespan by 10 and 6 years, respectively.33 
Therefore, renal function should be monitored in high-risk individu-
als such as those with obesity, insulin resistance and hypertension. 
Currently, RAS inhibitors are recommended as first-line treatments 
F I G U R E  1   AT1 blockade in conjunction with GLP-1r activation 
reduced kidney Nox 4 protein expression. Mean (±SE) kidney Nox 4 
(% change from LETO), and the representative western blot bands 
of Long-Evans Tokushima Otsuka (LETO; n = 7), Otsuka Long-
Evans Tokushima Fatty (OLETF; n = 9), OLETF + ARB (ARB; n = 8), 
OLETF + EXE (EXE; n = 7) and OLETF + ARB+EXE (Combo; n = 6). * 
P < .05 vs LETO; # P < .05 vs OLETF
F I G U R E  2   AT1 blockade normalizes kidney superoxide 
dismutase enzyme activity. Mean (±SE) activity of kidney (A) 
superoxide dismutase, (B) catalase and (C) glutathione peroxidase 
of Long-Evans Tokushima Otsuka (LETO; n = 7), Otsuka Long-Evans 
Tokushima Fatty (OLETF; n = 6-9), OLETF + ARB (ARB; n = 6-8), 
OLETF + EXE (EXE; n = 5-7) and OLETF + ARB+EXE (Combo; 
n = 5-6). * P < .05 vs LETO; # P < .05 vs OLETF
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for individuals with concomitant DM, hypertension and elevated 
ACR.34 Nevertheless, in individuals with DM and high cardiovascular 
risk, liraglutide (a GLP-1r agonist) added to standard diabetes treat-
ment (83% of participants were on RAS inhibitors) demonstrated 
that GLP-1r activation lowered the rates of the development and 
progression of kidney disease,25 suggesting that simultaneous RAS 
inhibition and GLP-1r activation may be an appropriate therapeutic 
option for kidney disease in high-risk individuals. Experimental stud-
ies have demonstrated that both RAS inhibitors and GLP-1r agonists 
improve renal function in diabetic animals by decreasing oxidative 
damage.19,21,22,35 Nevertheless, it remains unknown whether simul-
taneous AT1 blockade and GLP-1r activation improve renal oxidant 
balance and albuminuria in an insulin-resistant setting. Therefore, 
the objectives of this study were to evaluate (a) the potential of the 
added benefits of targeting two signalling pathways (AT1 and GLP-
1) that contribute to renal oxidant balance and (b) whether these 
benefits in renal oxidant balance translated into amelioration of al-
buminuria. To this end, we found that AT1 blockade and GLP-1r acti-
vation reduced renal Nox4 protein expression and NT levels and that 
combined administration did not have consistent additive effects. 
However, simultaneous AT1 blockade and GLP-1r activation reduced 
the UalbV more than monotherapy alone, suggesting that this is a 
critical early marker for evaluating the renal dysfunction associated 
with the onset of insulin resistance.
Oxidative damage is a result of increased oxidant production 
and/or reduced antioxidant capacity.36 Nox enzymes are the primary 
oxidant generators in the kidney,37 with Nox4 being the most promi-
nent in the renal cortex.23,38 Nox4 is constitutively active39 meaning 
that its higher expression in the renal cortex makes glomeruli and 
proximal tubules susceptible to Nox4-mediated oxidative injury. In 
rodent models of type 1 diabetes (T1D), global or podocyte dele-
tion/knockdown of Nox4 reduced ACR and attenuated glomerular 
structural changes.40-42 Furthermore, the deletion of Nox4 in Dahl 
salt-sensitive rats blunted the effects of a high Na+ diet on systolic 
blood pressure, albuminuria and glomerular injury.38 Collectively, 
these studies suggest that Nox4-mediated oxidant overproduction is 
the primary mediator of renal oxidative damage during impaired met-
abolic conditions. In the present study, renal Nox4 protein expres-
sion was increased, and renal SOD activity was decreased in OLETF 
rats indicating that impaired renal oxidant-antioxidant balance is a 
consequence of the early onset of insulin resistance. Furthermore, 
the hydrogen peroxide quenching enzymes (catalase and GPx) were 
not elevated in response to the increase in Nox4, which predomi-
nantly generates hydrogen peroxide, suggesting that this oxidative 
F I G U R E  3   Effects of AT1 blockade alone and in combination 
with GLP-1r activation on oxidative damage. Mean (±SE) urinary 
(A) 8-isoprostane excretion, (B) kidney nitrotyrosine and (C) 
4-hydroxynonenal, and the representative dot blots of Long-Evans 
Tokushima Otsuka (LETO; n = 7), Otsuka Long-Evans Tokushima 
Fatty (OLETF; n = 7-9), OLETF + ARB (ARB; n = 7-9), OLETF + EXE 
(EXE; n = 7) and OLETF + ARB+EXE (Combo; n = 5-6). * P < .05 vs 
LETO; # P < .05 vs OLETF
F I G U R E  4   AT1 blockade and GLP-1r activation ameliorate 
albuminuria. Mean (±SE) urinary albumin excretion of Long-Evans 
Tokushima Otsuka (LETO; n = 7), Otsuka Long-Evans Tokushima 
Fatty (OLETF; n = 9), OLETF + ARB (ARB; n = 9), OLETF + EXE 
(EXE; n = 7) and OLETF + ARB+EXE (Combo; n = 6). * P < .05 vs 
LETO; # P < .05 vs. OLETF; a P < .05 vs baseline for OLETF
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environment was likely driven by elevated cellular oxidant pro-
duction. Nevertheless, AT1 blockade or GLP-1r activation reduced 
Nox4 protein expression, and their combination had no additional 
benefits, suggesting that these two signalling pathways may share 
a common mediator of Nox4 regulation. The suppression of Nox4 
expression in the treatment groups likely reduced the necessity to 
increase catalase and GPx, and thus potentially explains the lack of a 
change in their activities. While Nox2 is also expressed in the kidney, 
albeit to a much lesser extent than Nox4,43 we performed additional 
measurements of phox47 translocation as previously described in 
the heart of Ang II-infused rats44 and did not observe a significant 
group effect (data not shown), suggesting that the oxidative damage 
observed was likely the primary result of Nox4-generated oxidants 
and not from Nox2.
Nox4 is induced by high glucose or Ang II,45-48 which are both 
elevated in obesity and insulin-resistant conditions.5,27 In this study, 
OLETF rats are characterized by fasting hyperglycaemia and in-
creased UAgtV, but only AT1 blockade reduced the glucose levels
31 
suggesting that overactivation of RAS contributes significantly to 
the early-onset hyperglycaemia. Conversely, UAgtV was reduced 
equally by AT1 blockade, GLP-1r activation and their combination, 
suggesting that these two signalling pathways may reduce Nox4 pro-
tein expression through their regulation of intrarenal Ang II levels. 
The decrease in Ang II-induced cellular damage in renal mesangial 
cells with GLP-1r agonism49 corroborates this previous contention.
Nitrotyrosine formation is a result of peroxynitrite production, 
which is a product formed by the reaction between nitric oxide and 
superoxide.50 Although Nox4 mainly generates hydrogen peroxide, 
it has been suggested that it may also generate superoxide,47,51,52 
which may then interact with nitric oxide to form peroxynitrite. The 
increase in Nox4 expression and NT levels, in the presence of re-
duced SOD, suggests that renal Nox4 may have generated sufficient 
superoxide, which was not sufficiently dismutased because of the 
suppressed levels of SOD, to promote nitrosative stress in the kid-
ney. The blockade of AT1, activation of GLP-1r and their combination 
effectively reduced Nox4 expression and ameliorated the suppres-
sion of SOD, which resulted in the equivalent reconciliation of the 
nitrotyrosine levels corroborating the Nox4 mediation of nitrosative 
stress. In mesangial cells, incubation with high glucose or Ang II in-
creased Nox4 expression, superoxide generation and peroxynitrite 
formation leading to the uncoupling of endothelial nitric-oxide syn-
thase and fibronectin formation.47,52 Furthermore, these data sug-
gest that AT1 blockade and activated GLP-1r signalling contribute 
equivalently to the reduction in oxidants in the kidney during insu-
lin resistance. Although GLP-1r activation did not significantly alter 
SOD activity here, in streptozotocin-induced diabetic Wistar rats, 
liraglutide treatment lowered the expressions of Nox4, and the sub-
units of Nox2, gp91phox and p47phox,21 suggesting that the protec-
tive effects come from decreasing oxidant production rather than 
oxidant detoxification.
F I G U R E  5   Effects of AT1 blockade 
alone and in combination with GLP-1r 
activation on glomerulosclerosis. Mean 
(±SE) PAS-positive area in glomerulus of 
Long-Evans Tokushima Otsuka (LETO; 
n = 7), Otsuka Long-Evans Tokushima 
Fatty (OLETF; n = 4), OLETF + ARB (ARB; 
n = 4), OLETF + EXE (EXE; n = 6) and 
OLETF + ARB+EXE (Combo; n = 5)
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Increased renal Ang II levels are associated with the pathophysi-
ology of renal disease.8 In the present study, UalbV and ACR were in-
creased in insulin-resistant OLETF rats at baseline, suggesting that the 
dysmetabolic condition in the model is sufficient to promote early-on-
set renal injury, which progresses rapidly over the following 6 weeks of 
age. The progression of the albuminuria is most likely attributed to Ang 
II-associated renal dysfunction in this model.53 While ARB and EXE 
individually provided modest improvements in UalbV suggesting that 
AT1 and GLP-1 signalling are contributing elements to the progression 
of the model-associated albuminuria, the combination of these treat-
ments completely ameliorated UalbV and ACR, suggesting that the ben-
efits of AT1 blockade and GLP-1r activation are additive. Additionally, 
while correction of the UalbV by creatinine excretion removed the sta-
tistical difference in UalbV in the ARB and EXE suggesting that subtle, 
non-significant changes in glomerular filtration partially contributed to 
the reduction in UalbV, the reduction in UalbV remained significant even 
after correcting for UcrtV, suggesting that the benefits of co-therapy 
were not significantly influenced by changes in filtration. While this 
was one of the few additive effects detected, it is highly biologically 
significant because a profound improvement in UalbV was observed 
despite the lack of consistent parallel improvements in oxidant/anti-
oxidant balance and oxidative/nitrosative damage, suggesting that the 
mechanisms driving proteinuria during the early stages of insulin resis-
tance are not primarily mediated by impaired redox balance signalling 
and the accompanying injury. Thus, ACR may serve as a critical marker 
for early detection before the kidney becomes irreversibly compro-
mised with the progression of the insulin resistance into frank type 2 
diabetes. This finding is in agreement with that previously reported in 
which 11 weeks of co-therapy with telmisartan (ARB) and linagliptin 
(dipeptidyl peptidase 4 inhibitor) in mice induced with T1D normal-
ized albuminuria, whereas the reductions with monotherapy were not 
statistically significant.54 Additionally, our findings support the results 
from the LEADER trial, which found that liraglutide added to standard 
diabetes treatment (83% of participants were on RAS inhibitors) low-
ered the rates of the development and progression of kidney disease, 
with these benefits being a result of a reduction in new onset of per-
sistent macroalbuminuria.25 Interestingly, the reductions in UalbV and 
ACR here were independent of improvements in glomerulosclerosis 
(PAS staining), suggesting that at this stage of the disease the improve-
ments in UalbV and ACR may be a result of altered albumin reabsorp-
tion55 rather than overt glomerular injury.
While the improvement in fasting plasma glucose with ARB was not 
accompanied by statistically significant reductions in plasma insulin and 
calculated HOMA-IR values, the reductions in these variables trended 
(P < .10) in the appropriate directions. Furthermore, these analyses in 
the present study were based on static plasma analyses, whereas we 
have demonstrated that the same dosage of ARB potently improves 
glucose tolerance and insulin resistance index calculations using the 
more robust glucose tolerance test in this model.27 Interestingly, ex-
enatide and the combination therapies did not translate into static 
improvements in either fasting plasma glucose or insulin, and thus cal-
culated HOMA-IR. While the present study was not designed to ex-
amine the mechanisms of peripheral glucose regulation, we speculate 
that the improvements in fasting glucose and glucose tolerance in this 
model27 stem from the maintenance of pancreatic health and potential 
amelioration of leptin resistance. This is based on our previous study27 
demonstrating that ARB partially normalized the hyperleptinaemia, 
which is characteristic of the OLETF. The progression of the diabetes in 
this model is associated with the development of leptin resistance.56,57 
Chronic blockade of AT1 with telmisartan improved glucose tolerance 
and other symptoms of the metabolic syndrome via improved leptin 
signalling and sensitivity associated with amelioration of the hyper-
leptinaemia,58,59 suggesting that the improvements in fasting plasma 
glucose in the present study were derived from similar mechanisms. In 
the STZ-induced diabetic mouse, exogenous leptin restored the insu-
linotropic effect of exenatide,60 suggesting that elevated leptin facili-
tates GLP-1-mediated effects on insulin signalling. In the present study, 
OLETF presented with the characteristic hyperleptinaemia, which is 
partially ameliorated with ARB and combination treatments. Consistent 
with clinical trials in humans,61 exenatide did not reduce plasma leptin 
and the effects of exenatide on circulating leptin must have been suffi-
cient to mask the benefits of ARB because the combination group also 
did not translate to a significant improvement in fasting plasma glucose 
despite an equivalent reduction in plasma leptin. While telmisartan59 
and an exenatide analogue62 have been shown to reduce body mass 
independently, body mass was only reduced in the combination group, 
suggesting that the lack of improvements in fasting plasma glucose and 
HOMA-IR was independent of decreases in body mass. The interac-
tions of these treatments on leptin receptor signalling and glucose me-
tabolism warrant further investigation.
4  | CONCLUSION
In summary, the present study demonstrates that combined GLP-1r 
activation and AT1 blockade produce an additive improvement in 
albuminuria, which is independent of any overt glomerular injury. 
Furthermore, we demonstrated that AT1 blockade, GLP-1r activa-
tion and their combination equally reduced UAgtV, renal Nox 4 pro-
tein expression and nitrotyrosine levels in the kidney. Interestingly, 
these beneficial effects in combination were independent of im-
provements in insulin resistance.
5  | METHODS
All experimental procedures were reviewed and approved by the 
Institutional Animal Care and Use Committees of Kagawa Medical 
University, Japan, and the University of California, Merced. The present 
manuscript complements our previous study using the same animals.31
5.1 | Animals
Male, eight-week-old male, Long-Evans Tokushima Otsuka (LETO) 
and Otsuka Long-Evans Tokushima Fatty (OLETF) rats were studied 
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(Otsuka Pharmaceutical Co. Ltd., Tokushima, Japan). Rats were di-
vided into the following groups: (a) untreated LETO (n = 7) + vehi-
cle (0.5% methylcellulose by oral gavage once daily), (b) untreated 
OLETF (n = 9) + vehicle, (c) OLETF + ARB (ARB; 10 mg olmesartan/
kg/d by oral gavage once daily for 42 days; n = 9), (d) OLETF + GLP-1 
receptor agonist (EXE; 10 µg exenatide/kg/d by osmotic mini-pumps 
for 42 days; n = 7) and (e) OLETF + ARB +EXE (Combo; n = 6). Initially, 
animals in the OLETF groups were assigned so that the initial mean 
BM of the groups was within 5% of each other. Animals were housed 
in individual metabolic cages, and urine was collected at baseline and 
40 days following the start of the treatments. After collection, urine 
samples were centrifuged (3000 g x 15 minutes at 4°C), and an ali-
quot transferred to a cryovial and immediately stored at −20°C for 
later analyses. All animals were housed in a specific pathogen-free 
facility under temperature (23°C) and humidity-controlled (55%) 
conditions on a 12-h light-dark cycle. All animals were given free ac-
cess to water and standard laboratory chow (Teklad Diets, Madison, 
WI). At 16 weeks of age, all tissues were harvested from animals.
5.2 | Body mass and food intake
BM was measured daily to calculate the appropriate ARB dose.31
5.3 | Tissue collection
At 16 weeks of age (following 42 days of treatment), animals were 
fasted for 12 hours, and tissues were collected the following morn-
ing. After BM measurements had been obtained, animals were 
decapitated, and trunk blood was collected into chilled vials con-
taining 50 mmol/L EDTA and protease inhibitor cocktail (PIC; Sigma-
Aldrich). Immediately following, retroperitoneal and epididymal fat 
masses, and the left kidney were removed, their mass was recorded, 
and the kidney was snap-frozen in liquid nitrogen and stored at 
−80°C until analysed. Additionally, the right kidney was perfused 
with PBS, removed and a mid-transverse section was fixed in 4% 
paraformaldehyde, dehydrated and embedded in paraffin. Blood 
samples were centrifuged (3000 g x 15 minutes at 4°C), and plasma 
was transferred to cryovials and stored at −80°C for later analyses.
5.4 | Western blot
Renal protein expression of Nox4 was determined as previously 
described.63 Blots were incubated with Nox4 (1:500; Abcam) and 
β-actin (1:500; Santa Cruz Biotechnology) antibodies. Membranes 
were washed, incubated for 1 hour with specific secondary antibod-
ies (IRDye: LI-COR Biosciences) in TBS-T + 5% non-fat milk + 0.01% 
SDS, rewashed and scanned in an Odyssey infrared imager (LI-COR 
Biosciences). In addition to consistently loading the same amount of 
total protein per well, densitometry values were further normalized 
by correcting for the densitometry values of β-actin.
5.5 | Renal oxidative injury and antioxidant 
enzyme activities
A piece of frozen kidney cortex was homogenized in 50 mmol/L po-
tassium phosphate buffer containing EDTA, PIC (Thermo) and PMSF 
(EMD Millipore). Subsequent supernatants were used to measure 
renal NT and 4-HNE levels as markers of oxidative renal injury as pre-
viously described.44 Membranes were incubated with NT (1:1000; 
Cell Signaling, Danvers, MA) and 4-HNE (1:1000; EMD Millipore) an-
tibodies and developed similarly to western blots (described above). 
Uniformed protein loading was confirmed by Ponceau S staining. 
Renal SOD, catalase and GPx activities were measured using com-
mercially available kits (Cayman Chemical, Ann Arbor, MI) as previ-
ously described.63,64 Total protein content was measured with the 
Bradford protein assay (Bio-Rad Laboratories, Hercules, CA) and 
used to normalize enzyme activities.63,64
5.6 | Biochemical analyses and homeostasis model 
assessment of insulin resistance
Fasting plasma glucose was measured using an Analox GM7 analyzer 
(Analox Instruments). Fasting plasma creatinine (Sigma-Aldrich), in-
sulin (EMD Millipore) and leptin (R&D Systems) were measured using 
commercially available kits. All samples were analysed in duplicate 
and ran in a single assay with intra-assay coefficients of variability 
of <10%. HOMA-IR was calculated as follows: HOMA-IR = (fasting 
plasma glucose (mg/dL) x fasting plasma insulin (µU/mL))/2.430, as 
previously described in rats.65
5.7 | Urine analyses
Levels of urinary angiotensinogen (BL America), urinary albumin 
(Bethyl, Montgomery, TX), urinary 8-isoprostane (Cayman Chemical) 
and creatinine (Sigma-Aldrich) were measured using commercially 
available colorimetric kits. Urine albumin concentrations were meas-
ured using a Hitachi 7020 chemistry analyzer (Diamond Diagnostics). 
Urinary excretion of each variable was calculated as the product of 
daily urine volume and urinary concentration. Additionally, urinary 
albumin excretion (UalbV) was further corrected for urinary creati-
nine excretion to account for potential effects of changes in glo-
merular filtration. All samples were analysed in duplicate and run in 
a single assay with intra-assay, per cent coefficients of variability of 
<10% for all assays.
5.8 | Histology
Histological evaluation of the glomeruli by periodic acid-Schiff stain-
ing (PAS) at 16 weeks of age was performed as described previously.66 
The ratio of the affected lesions to each glomerulus was calculated 
using the ImageJ software. For each glomerulus, the affected lesion 
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where the intensity was beyond a threshold calculated by the back-
ground signal was measured automatically by the software, and this 
affected area, in turn, was divided by the total area of the glomerulus. 
For each kidney sample, 15 glomeruli were examined, and the aver-
aged percentages of the affected lesions were obtained. 
5.9 | Statistics
Means (± standard error) were compared by one-way ANOVA fol-
lowed by Newman-Keuls or Games-Howell post hoc test. For urinary 
albumin excretion (UalbV), we used a two-factor repeated-measures 
ANOVA with time as a within-subjects factor and group as a between-
subjects factor followed by pairwise comparisons using a Bonferroni 
correction. Means were considered significantly different at P < .05, 
and analyses were performed with SPSS version 24 (IBM).
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